

# Agnieszka Wozniak

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2263185/publications.pdf>

Version: 2024-02-01

144  
papers

5,207  
citations

87888

38  
h-index

95266

68  
g-index

146  
all docs

146  
docs citations

146  
times ranked

6205  
citing authors

#	ARTICLE	IF	CITATIONS
1	PhAc-ALGP-Dox, a Novel Anticancer Prodrug with Targeted Activation and Improved Therapeutic Index. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 568-581.	4.1	4
2	Enhanced Antitumor Efficacy of PhAc-ALGP-Dox, an Enzyme-Activated Doxorubicin Prodrug, in a Panel of THOP1-Expressing Patient-Derived Xenografts of Soft Tissue Sarcoma. <i>Biomedicines</i> , 2022, 10, 862.	3.2	1
3	Machine learning for rhabdomyosarcoma histopathology. <i>Modern Pathology</i> , 2022, 35, 1193-1203.	5.5	9
4	In Vivo Evaluation of Fibroblast Growth Factor Receptor Inhibition in Mouse Xenograft Models of Gastrointestinal Stromal Tumor. <i>Biomedicines</i> , 2022, 10, 1135.	3.2	4
5	Correlation of Immunological and Molecular Profiles with Response to Crizotinib in Alveolar Soft Part Sarcoma: An Exploratory Study Related to the EORTC 90101 "CREATE" Trial. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5689.	4.1	2
6	Pan-Cancer Detection and Typing by Mining Patterns in Large Genome-Wide Cell-Free DNA Sequencing Datasets. <i>Clinical Chemistry</i> , 2022, 68, 1164-1176.	3.2	6
7	Enapotamab Vedotin, an AXL-Specific Antibody-Drug Conjugate, Demonstrates Antitumor Efficacy in Patient-Derived Xenograft Models of Soft Tissue Sarcoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7493.	4.1	3
8	Plocabulin, a Novel Tubulin Inhibitor, Has Potent Antitumour Activity in Patient-Derived Xenograft Models of Soft Tissue Sarcoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7454.	4.1	1
9	Establishment of an Academic Tissue Microarray Platform as a Tool for Soft Tissue Sarcoma Research. <i>Sarcoma</i> , 2021, 2021, 1-12.	1.3	4
10	Molecular Biomarkers of Response to Eribulin in Patients with Leiomyosarcoma. <i>Clinical Cancer Research</i> , 2021, 27, 3106-3115.	7.0	5
11	Randomised phase 2 study comparing the efficacy and safety of the oral tyrosine kinase inhibitor nintedanib with single agent ifosfamide in patients with advanced, inoperable, metastatic soft tissue sarcoma after failure of first-line chemotherapy: EORTC-1506-STBSC "ANITA" European Journal of Cancer, 2021, 152, 26-40.	2.8	10
12	A Robust Method for Sample Preparation of Gastrointestinal Stromal Tumour for LC/MS Untargeted Metabolomics. <i>Metabolites</i> , 2021, 11, 554.	2.9	4
13	Comprehensive Molecular Analysis of Inflammatory Myofibroblastic Tumors Reveals Diverse Genomic Landscape and Potential Predictive Markers for Response to Crizotinib. <i>Clinical Cancer Research</i> , 2021, 27, 6737-6748.	7.0	12
14	Long-term efficacy update of crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumour from EORTC trial 90101 CREATE. <i>European Journal of Cancer</i> , 2021, 156, 12-23.	2.8	26
15	Histopathological and Molecular Profiling of Clear Cell Sarcoma and Correlation with Response to Crizotinib: An Exploratory Study Related to EORTC 90101 "CREATE" Trial. <i>Cancers</i> , 2021, 13, 6057.	3.7	9
16	Anti-tumor activity of the MDM2-TP53 inhibitor BI-907828 in dedifferentiated liposarcoma patient-derived xenograft models harboring MDM2 amplification. <i>Clinical and Translational Oncology</i> , 2020, 22, 546-554.	2.4	31
17	Plocabulin, a novel tubulin inhibitor, has potent antitumor activity in patient-derived xenograft models of gastrointestinal stromal tumors. <i>Translational Oncology</i> , 2020, 13, 100832.	3.7	9
18	MicroRNA expression profiles in molecular subtypes of clear-cell renal cell carcinoma are associated with clinical outcome and repression of specific mRNA targets. <i>PLoS ONE</i> , 2020, 15, e0238809.	2.5	5

#	ARTICLE	IF	CITATIONS
19	Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 "CaboGIST". <i>European Journal of Cancer</i> , 2020, 134, 62-74.	2.8	42
20	Differential antitumor activity of compounds targeting the ubiquitin-proteasome machinery in gastrointestinal stromal tumor (GIST) cells. <i>Scientific Reports</i> , 2020, 10, 5178.	3.3	8
21	Abstract 4280: Potential molecular biomarkers of response to eribulin in patients with leiomyosarcoma. , 2020, , .		0
22	Abstract 1676: Plocabulin, a novel tubulin inhibitor, has antitumor activity in various patient-derived xenograft models of soft tissue sarcoma. , 2020, , .		0
23	Abstract 5438: Establishment of an academic tissue microarray platform as an efficient tool for soft tissue sarcoma research. , 2020, , .		0
24	Abstract 1117: XenoSarc: Patient-derived xenograft (PDX) models of soft tissue sarcoma (STS) and their histopathological and molecular characterization. , 2020, , .		0
25	Abstract 794: Molecular analysis of archival inflammatory myofibroblastic tumor tissue samples from EORTC 90101 "CREATE" and correlation with response to crizotinib. , 2020, , .		0
26	Abstract 3191: Detection of molecular drivers in inflammatory myofibroblastic tumor: study on archival tissue from EORTC 90101 "CREATE" phase II clinical trial. , 2020, , .		0
27	Long-Term Outcomes in Clear-Cell Renal Cell Carcinoma Patients Treated with Complete Metastasectomy. <i>Kidney Cancer</i> , 2020, 4, 177-183.	0.4	4
28	Title is missing!. , 2020, 15, e0238809.		0
29	Title is missing!. , 2020, 15, e0238809.		0
30	Title is missing!. , 2020, 15, e0238809.		0
31	Title is missing!. , 2020, 15, e0238809.		0
32	Assessment of the platelet-derived growth factor receptor alpha antibody olaratumab in a panel of patient-derived soft tissue sarcoma xenografts. <i>BMC Cancer</i> , 2019, 19, 724.	2.6	6
33	Clear-cell Renal Cell Carcinoma: Molecular Characterization of IMDC Risk Groups and Sarcomatoid Tumors. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e981-e994.	1.9	34
34	Retrospective Analysis of Patients with Advanced Liposarcoma in a Tertiary Referral Center. <i>Oncology Research and Treatment</i> , 2019, 42, 396-404.	1.2	10
35	SS18-SSX "Dependent YAP/TAZ Signaling in Synovial Sarcoma. <i>Clinical Cancer Research</i> , 2019, 25, 3718-3731.	7.0	36
36	Establishment and Characterization of Histologically and Molecularly Stable Soft-tissue Sarcoma Xenograft Models for Biological Studies and Preclinical Drug Testing. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1168-1178.	4.1	23

#	ARTICLE	IF	CITATIONS
37	PLX9486 shows anti-tumor efficacy in patient-derived, tyrosine kinase inhibitor-resistant KIT-mutant xenograft models of gastrointestinal stromal tumors. <i>Clinical and Experimental Medicine</i> , 2019, 19, 201-210.	3.6	13
38	Anagrelide for Gastrointestinal Stromal Tumor. <i>Clinical Cancer Research</i> , 2019, 25, 1676-1687.	7.0	14
39	Robust Activity of Avapritinib, Potent and Highly Selective Inhibitor of Mutated KIT, in Patient-derived Xenograft Models of Gastrointestinal Stromal Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 609-618.	7.0	63
40	Abstract 388: SS18-SSX modulates YAP/TAZ-TEAD transcriptional activity in synovial sarcoma. , 2019, , .		0
41	Molecular Subtypes of Clear-cell Renal Cell Carcinoma are Prognostic for Outcome After Complete Metastasectomy. <i>European Urology</i> , 2018, 74, 474-480.	1.9	72
42	Polymorphisms in the Von Hippel-Lindau Gene Are Associated With Overall Survival in Metastatic Clear-Cell Renal-Cell Carcinoma Patients Treated With VEGFR Tyrosine Kinase Inhibitors. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 266-273.	1.9	11
43	Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer phase 2 trial 90101 CREATE). <i>Lancet Respiratory Medicine</i> . 2018. 6. 431-441.	10.7	134
44	Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 CREATE. <i>Annals of Oncology</i> , 2018, 29, 758-765.	1.2	67
45	Retrospective Analysis of Outcome of Patients with Metastatic Leiomyosarcoma in a Tertiary Referral Center. <i>Oncology Research and Treatment</i> , 2018, 41, 206-213.	1.2	13
46	The tyrosine kinase inhibitor crizotinib does not have clinically meaningful activity in heavily pre-treated patients with advanced alveolar rhabdomyosarcoma with FOXO rearrangement: European Organisation for Research and Treatment of Cancer phase 2 trial 90101 CREATE. <i>European Journal of Cancer</i> , 2018, 94, 156-167.	2.8	35
47	Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated With Outcome During Pazopanib Therapy in the Metastatic Setting. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e605-e612.	1.9	37
48	Primary myxoid mesenchymal tumour with intracranial location: report of a case with a EWSR1-ATF1 fusion. <i>Histopathology</i> , 2018, 72, 880-883.	2.9	37
49	Effect of crizotinib on disease control in patient with advanced papillary renal cell carcinoma type 1 with MET mutations or amplification: Final results of EORTC 90101 CREATE. <i>Journal of Clinical Oncology</i> , 2018, 36, 580-580.	1.6	1
50	Activity and safety of crizotinib in patients with advanced, metastatic alveolar soft part sarcoma (ASPS) with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase 2 trial 90101 CREATE. <i>Journal of Clinical Oncology</i> , 2018, 36, 11540-11540.	1.6	1
51	Abstract 1031: XenoSarc: Patient-derived xenograft (PDX) models of soft tissue sarcoma (STS) an update on a preclinical platform for early drug testing. , 2018, , .		0
52	Abstract CT045: Prospective precision medicine trial of crizotinib (C) in patients (pts) with advanced, inoperable inflammatory myofibroblastic tumor (IMFT) with and without ALK alterations: EORTC phase II study 90101 "CREATE". <i>Cancer Research</i> , 2018, 78, CT045-CT045.	0.9	1
53	Abstract 3840: Plocabulin, a tubulin inhibitor, presents antitumor activity in patient-derived xenograft (PDX) models of gastrointestinal stromal tumor (GIST). , 2018, , .		1
54	Volatile organic compounds in gastrointestinal stromal tumour tissue originating from patient-derived xenografts. <i>Journal of Breath Research</i> , 2017, 11, 037101.	3.0	2

#	ARTICLE	IF	CITATIONS
55	<i>In Vivo</i> Antitumoral Efficacy of PhAc-ALGP-Doxorubicin, an Enzyme-Activated Doxorubicin Prodrug, in Patient-Derived Soft Tissue Sarcoma Xenograft Models. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1566-1575.	4.1	15
56	Identification of microRNA biomarkers for response of advanced soft tissue sarcomas to eribulin: Translational results of the EORTC 62052 trial. <i>European Journal of Cancer</i> , 2017, 75, 33-40.	2.8	22
57	A precision therapy against cancers driven by <i>KIT/PDGFR</i> mutations. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	157
58	Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 â€œCREATEâ€™. <i>Annals of Oncology</i> , 2017, 28, 3000-3008.	1.2	70
59	Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial. <i>European Journal of Cancer</i> , 2017, 87, 147-163.	2.8	108
60	New targets and therapies for gastrointestinal stromal tumors. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 1117-1129.	2.4	18
61	Abstract 2081: Robust activity of BLU-285, a potent and highly selective inhibitor of mutant KIT and PDGFR $\pm$ , in patient-derived xenograft (PDX) models of gastrointestinal stromal tumor (GIST)., 2017, , .		0
62	Abstract 4811: XenoSarc: Patient-derived xenograft (PDX) models of soft tissue sarcoma (STS), an update on a preclinical platform for early drug testing. , 2017, , .		0
63	Overcoming Cost Implications of Mutational Analysis in Patients with Gastrointestinal Stromal Tumors: A Pragmatic Approach. <i>Oncology Research and Treatment</i> , 2016, 39, 811-816.	1.2	14
64	Cabozantinib Is Active against Human Gastrointestinal Stromal Tumor Xenografts Carrying Different <i>KIT</i> Mutations. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2845-2852.	4.1	30
65	Biology and management of clear cell sarcoma: state of the art and future perspectives. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 839-845.	2.4	31
66	Abstract CT006: Crizotinib achieves objective responses and long-lasting disease control in patients (pts) with metastatic papillary renal cell carcinoma type 1 (PRCC1) with somatic MET mutations. EORTC phase II trial 90101 â€œCREATEâ€™, 2016, , .		4
67	Deep sequencing reveals microRNAs predictive of antiangiogenic drug response. <i>JCI Insight</i> , 2016, 1, e86051.	5.0	39
68	Efficacy of BLU-285, a novel, potent inhibitor of Exon 17 Mutant KIT and PDGFR D842V, in patient-derived xenograft model of gastrointestinal stromal tumor (GIST).. <i>Journal of Clinical Oncology</i> , 2016, 34, 11030-11030.	1.6	4
69	Single-center experience with advanced liposarcoma (LPS): Overall survival (OS), prognostic factors and chemotherapy outcome.. <i>Journal of Clinical Oncology</i> , 2016, 34, e22521-e22521.	1.6	0
70	Single-center experience with metastatic leiomyosarcoma: Survival, prognostic factors and outcome of chemotherapy.. <i>Journal of Clinical Oncology</i> , 2016, 34, e22531-e22531.	1.6	0
71	Abstract 5197: Patient-derived xenograft (PDX) models of soft tissue sarcoma (STS): a preclinical platform for early drug testing. , 2016, , .		0
72	Therapeutic Efficacy Assessment of CK6, a Monoclonal KIT Antibody, in a Panel of Gastrointestinal Stromal Tumor Xenograft Models. <i>Translational Oncology</i> , 2015, 8, 112-118.	3.7	14

#	ARTICLE	IF	CITATIONS
73	Targeted Therapy in Gastrointestinal Stromal Tumors. <i>Current Clinical Pathology</i> , 2015, , 163-196.	0.0	1
74	Abstract 1460: Establishment and characterization of a panel of patient-derived soft tissue sarcoma (STS) xenograft models for in vivo testing of novel therapeutic approaches. <i>Cancer Research</i> , 2015, 75, 1460-1460.	0.9	17
75	Abstract 775: Anti-tumor effects of dovitinib, a multi-target kinase inhibitor, in patient-derived gastrointestinal stromal tumor (GIST) xenograft models. , 2015, , .		3
76	Activity of crizotinib (C) in patients (pts) with clear cell sarcoma (CCSA) in EORTC phase II trial 90101 "CREATE".. <i>Journal of Clinical Oncology</i> , 2015, 33, 10542-10542.	1.6	4
77	Efficacy of an enzyme-activated doxorubicin prodrug in patient-derived dedifferentiated liposarcoma and synovial sarcoma xenografts.. <i>Journal of Clinical Oncology</i> , 2015, 33, e13539-e13539.	1.6	1
78	Anti-tumor effects of dovitinib in patient-derived gastrointestinal stromal tumor (GIST) xenograft models.. <i>Journal of Clinical Oncology</i> , 2015, 33, 10532-10532.	1.6	0
79	Abstract 1461: A panel of patient derived gastrointestinal stromal tumors (GIST) xenograft models for in vivo preclinical drug testing. , 2015, , .		0
80	Abstract 774: Cabozantinib, a multi-target receptor tyrosine kinase inhibitor, decreases tumor growth and angiogenesis in a patient-derived dedifferentiated liposarcoma xenograft. , 2015, , .		0
81	Abstract 5353: Efficacy of an innovative, enzyme-activated doxorubicin prodrug in patient-derived dedifferentiated liposarcoma and synovial sarcoma xenograft models. , 2015, , .		1
82	Pazopanib, a Receptor Tyrosine Kinase Inhibitor, Suppresses Tumor Growth through Angiogenesis in Dedifferentiated Liposarcoma Xenograft Models. <i>Translational Oncology</i> , 2014, 7, 665-671.	3.7	38
83	Identification of a novel, recurrent <i>MBTD1</i> – <i>Xorf67</i> fusion in low-grade endometrial stromal sarcoma. <i>International Journal of Cancer</i> , 2014, 134, 1112-1122.	5.1	117
84	Frequent mono-allelic loss associated with deficient PTEN expression in imatinib-resistant gastrointestinal stromal tumors. <i>Modern Pathology</i> , 2014, 27, 1510-1520.	5.5	27
85	Tumor Genotype Is an Independent Prognostic Factor in Primary Gastrointestinal Stromal Tumors of Gastric Origin: A European Multicenter Analysis Based on ConticaGIST. <i>Clinical Cancer Research</i> , 2014, 20, 6105-6116.	7.0	129
86	Phosphoinositide 3-Kinase Inhibitors Combined with Imatinib in Patient-Derived Xenograft Models of Gastrointestinal Stromal Tumors: Rationale and Efficacy. <i>Clinical Cancer Research</i> , 2014, 20, 6071-6082.	7.0	45
87	Soft Tissue Sarcoma: An Update on Systemic Treatment Options for Patients with Advanced Disease. <i>Oncology Research and Treatment</i> , 2014, 37, 355-362.	1.2	88
88	Unbiased Compound Screening Identifies Unexpected Drug Sensitivities and Novel Treatment Options for Gastrointestinal Stromal Tumors. <i>Cancer Research</i> , 2014, 74, 1200-1213.	0.9	40
89	Characterization and assessment of the sensitivity and resistance of a newly established human gastrointestinal stromal tumour xenograft model to treatment with tyrosine kinase inhibitors. <i>Clinical Sarcoma Research</i> , 2014, 4, 10.	2.3	24
90	Metastatic potential is determined early in synovial sarcoma development and reflected by tumor molecular features. <i>International Journal of Biochemistry and Cell Biology</i> , 2014, 53, 505-513.	2.8	34

#	ARTICLE	IF	CITATIONS
91	Clinical Presentation, Pathological Features and Natural Course of Metastatic Uveal Melanoma, an Orphan and Commonly Fatal Disease. <i>Oncology</i> , 2014, 86, 185-189.	1.9	21
92	Improvement of existing risk classifications in primary gastrointestinal stromal tumors (GIST).. <i>Journal of Clinical Oncology</i> , 2014, 32, 10517-10517.	1.6	1
93	MiR-17-92 and miR-221/222 cluster members target KIT and ETV1 in human gastrointestinal stromal tumours. <i>British Journal of Cancer</i> , 2013, 109, 1625-1635.	6.4	73
94	What are the current outcomes of advanced gastrointestinal stromal tumors: who are the long-term survivors treated initially with imatinib?. <i>Medical Oncology</i> , 2013, 30, 765.	2.5	20
95	Defining pseudoprogression in glioblastoma multiforme. <i>European Journal of Neurology</i> , 2013, 20, 1335-1341.	3.3	48
96	The DREAM Complex Mediates GIST Cell Quiescence and Is a Novel Therapeutic Target to Enhance Imatinib-Induced Apoptosis. <i>Cancer Research</i> , 2013, 73, 5120-5129.	0.9	72
97	Chromosome Instability Accounts for Reverse Metastatic Outcomes of Pediatric and Adult Synovial Sarcomas. <i>Journal of Clinical Oncology</i> , 2013, 31, 608-615.	1.6	135
98	A Potent Combination of the Novel PI3K Inhibitor, GDC-0941, with Imatinib in Gastrointestinal Stromal Tumor Xenografts: Long-Lasting Responses after Treatment Withdrawal. <i>Clinical Cancer Research</i> , 2013, 19, 620-630.	7.0	64
99	Identification of potential molecular biomarkers for response of soft tissue sarcoma to eribulin: Translational results of EORTC trial 62052.. <i>Journal of Clinical Oncology</i> , 2013, 31, 10573-10573.	1.6	2
100	Prognostic value of KIT/PDGFR mutations in gastrointestinal stromal tumours (GIST): Polish Clinical GIST Registry experience. <i>Annals of Oncology</i> , 2012, 23, 353-360.	1.2	125
101	The HSP90 Inhibitor, AT13387, Is Effective against Imatinib-Sensitive and -Resistant Gastrointestinal Stromal Tumor Models. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 1799-1808.	4.1	53
102	Promoting role of cholecystokinin 2 receptor (CCK2R) in gastrointestinal stromal tumour pathogenesis. <i>Journal of Pathology</i> , 2012, 228, 565-574.	4.5	14
103	Mitotic Checkpoints and Chromosome Instability Are Strong Predictors of Clinical Outcome in Gastrointestinal Stromal Tumors. <i>Clinical Cancer Research</i> , 2012, 18, 826-838.	7.0	118
104	The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study. <i>BMC Cancer</i> , 2012, 12, 107.	2.6	62
105	Efficacy of a phosphoinositol 3 kinase (PI3K) inhibitor in gastrointestinal stromal tumor (GIST) models.. <i>Journal of Clinical Oncology</i> , 2012, 30, 10030-10030.	1.6	2
106	Neuroblastic Tumors – Status and Role of HER Family Receptors. <i>Pediatric Cancer</i> , 2012, , 89-98.	0.0	0
107	Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour – The impact of tumour rupture on patient outcomes. <i>European Journal of Surgical Oncology</i> , 2011, 37, 890-896.	1.0	153
108	Advances in Molecular Characterization and Targeted Therapy in Dermatofibrosarcoma Protuberans. <i>Sarcoma</i> , 2011, 2011, 1-6.	1.3	37

#	ARTICLE	IF	CITATIONS
109	The Heat Shock Protein 90 Inhibitor IPI-504 Induces KIT Degradation, Tumor Shrinkage, and Cell Proliferation Arrest in Xenograft Models of Gastrointestinal Stromal Tumors. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 1897-1908.	4.1	43
110	Expression and significance of HER family receptors in neuroblastic tumors. <i>Clinical and Experimental Metastasis</i> , 2011, 28, 271-282.	3.3	20
111	Frequent activation of EGFR in advanced chordomas. <i>Clinical Sarcoma Research</i> , 2011, 1, 4.	2.3	36
112	Clinical utility of the new American Joint Committee on Cancer staging system for gastrointestinal stromal tumors. <i>Cancer</i> , 2011, 117, 4916-4924.	4.1	47
113	The Novel HSP90 Inhibitor, IPI-493, Is Highly Effective in Human Gastrointestinal Stromal Tumor Xenografts Carrying Heterogeneous <i>KIT</i> Mutations. <i>Clinical Cancer Research</i> , 2011, 17, 5604-5614.	7.0	48
114	Retroperitoneal Dedifferentiated Liposarcomas with Production of $\beta$ -Human Chorionic Gonadotropin – a Distinct Sarcoma Entity?. <i>Onkologie</i> , 2011, 34, 122-125.	0.8	5
115	Coactivated Platelet-Derived Growth Factor Receptor $\beta$ and Epidermal Growth Factor Receptor Are Potential Therapeutic Targets in Intimal Sarcoma. <i>Cancer Research</i> , 2010, 70, 7304-7314.	0.9	80
116	Prognostic significance of HER2 expression in neuroblastic tumors. <i>Modern Pathology</i> , 2010, 23, 1261-1268.	5.5	13
117	MYC High Level Gene Amplification Is a Distinctive Feature of Angiosarcomas after Irradiation or Chronic Lymphedema. <i>American Journal of Pathology</i> , 2010, 176, 34-39.	3.8	276
118	Implications of Mutational Analysis for the Management of Patients With Gastrointestinal Stromal Tumors and the Application of Targeted Therapies. <i>Cancer Investigation</i> , 2010, 28, 839-848.	1.3	16
119	High Efficacy of Panobinostat Towards Human Gastrointestinal Stromal Tumors in a Xenograft Mouse Model. <i>Clinical Cancer Research</i> , 2009, 15, 4066-4076.	7.0	53
120	Complex tumor-specific t(X;18) in seven synovial sarcoma tumors. <i>Cancer Genetics and Cytogenetics</i> , 2009, 189, 118-121.	1.0	5
121	Posttransplant Epstein-Barr Virus-Associated Myogenic Tumors: Case Report and Review of the Literature. <i>American Journal of Transplantation</i> , 2008, 8, 253-258.	4.7	36
122	Rectal gastrointestinal stromal tumors associated with a novel germline <i>KIT</i> mutation. <i>International Journal of Cancer</i> , 2008, 122, 2160-2164.	5.1	30
123	Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases. <i>Modern Pathology</i> , 2008, 21, 476-484.	5.5	165
124	Periventricular heterotopia in a boy with interstitial deletion of chromosome 4p. <i>European Journal of Medical Genetics</i> , 2008, 51, 165-171.	1.3	12
125	Activity of Dasatinib, a Dual SRC/ABL Kinase Inhibitor, and IPI-504, a Heat Shock Protein 90 Inhibitor, against Gastrointestinal Stromal Tumor-Associated PDGFRAD842V Mutation. <i>Clinical Cancer Research</i> , 2008, 14, 5749-5758.	7.0	116
126	Clinical impact of trabectedin (ecteinascidin-743) in advanced/metastatic soft tissue sarcoma. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 1609-1618.	1.8	50



#	ARTICLE	IF	CITATIONS
127	Changes in expression of serine proteases HtrA1 and HtrA2 during estrogen-induced oxidative stress and nephrocarcinogenesis in male Syrian hamster.. Acta Biochimica Polonica, 2008, 55, 9-20.	0.5	20
128	Trabectedin (ET-743): evaluation of its use in advanced soft-tissue sarcoma. Future Oncology, 2007, 3, 381-392.	2.4	27
129	Malignant Ectomesenchymoma: Genetic Profile Reflects Rhabdomyosarcomatous Differentiation. Diagnostic Molecular Pathology, 2007, 16, 243-248.	2.1	19
130	A girl with duplication 9q34 syndrome. American Journal of Medical Genetics, Part A, 2007, 143A, 2019-2023.	1.2	16
131	Array CGH analysis in primary gastrointestinal stromal tumors: Cytogenetic profile correlates with anatomic site and tumor aggressiveness, irrespective of mutational status. Genes Chromosomes and Cancer, 2007, 46, 261-276.	2.8	106
132	Presence of homozygous KIT exon 11 mutations is strongly associated with malignant clinical behavior in gastrointestinal stromal tumors. Laboratory Investigation, 2007, 87, 1029-1041.	3.7	92
133	Risk Criteria and Prognostic Factors for Predicting Recurrences After Resection of Primary Gastrointestinal Stromal Tumor. Annals of Surgical Oncology, 2007, 14, 2018-2027.	1.5	227
134	Predictive factors for long-term effects of imatinib therapy in patients with inoperable/metastatic CD117(+) gastrointestinal stromal tumors (GISTs). Journal of Cancer Research and Clinical Oncology, 2007, 133, 589-597.	2.5	31
135	Rearrangement of the COL12A1 and COL4A5 genes in subungual exostosis: molecular cytogenetic delineation of the tumor-specific translocation t(X;6)(q13-14;q22). International Journal of Cancer, 2006, 118, 1972-1976.	5.1	53
136	Molecular pathogenesis of multiple gastrointestinal stromal tumors in NF1 patients. Human Molecular Genetics, 2006, 15, 1015-1023.	2.9	195
137	Loss of heterozygosity on chromosome 22q in gastrointestinal stromal tumors (GISTs): a study on 50 cases. Laboratory Investigation, 2005, 85, 237-247.	3.7	34
138	KIT overexpression and amplification in gastrointestinal stromal tumors (GISTs). Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2005, 1741, 165-172.	3.8	35
139	Loss of heterozygosity in 73 human thyroid tumors. Neuroendocrinology Letters, 2005, 26, 521-5.	0.2	2
140	Title is missing!. Journal of Neuro-Oncology, 2003, 64, 284-284.	2.9	0
141	A unique occurrence of a cerebral atypical teratoid/rhabdoid tumor in an infant and a spinal canal primitive neuroectodermal tumor in her father. Journal of Neuro-Oncology, 2003, 61, 219-225.	2.9	16
142	Partial trisomy of distal 5q and partial monosomy of Xp as a result of mating between two translocation carriers: a female with a balanced translocation t(X;5)(p11;q31) and a male with a der(13;14)(q10;q10) – a case report and a family study. Annales De G�n�tologie, 2002, 45, 143-146.	0.4	7
143	The Neurofibromatosis Type 2 Gene Is Mutated in Perineurial Cell Tumors. American Journal of Pathology, 2001, 158, 1223-1229.	3.8	70
144	Mutations in Exons 9 and 13 of KIT Gene Are Rare Events in Gastrointestinal Stromal Tumors. American Journal of Pathology, 2000, 157, 1091-1095.	3.8	299